Plasma Determination of Glucagon-Like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure
Information source: Imperial College London
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Short Bowel Syndrome
Phase: N/A
Status: Recruiting
Sponsored by: Imperial College London Official(s) and/or principal investigator(s): Alastair Forbes, Principal Investigator, Affiliation: University College London Hospitals
Overall contact: Katharina Wallis, Email: katharina.wallis@ic.ac.uk
Summary
The purpose of this study is to investigate the theory that the plasma level of Glucagon
like peptide 2 (GLP-2) in patients with intestinal failure can predict their clinical
recovery.
Clinical Details
Official title: Plasma Determination of Glucagon-Like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure
Study design: Observational Model: Defined Population, Time Perspective: Longitudinal
Detailed description:
When major segments of small bowel have been removed surgically, or damaged by disease, the
length of the residual bowel may be inadequate to maintain overall nutrition and the net
result is described as "intestinal failure".
Without medical intervention, patients with intestinal failure become malnourished and
dehydrated because their remaining intestine is unable to absorb enough water, vitamins and
other nutrients from the ingested food. Intravenous feeding offers life saving treatment
but causes complications like infections and liver problems. It also poses enormous strain
on day to day life.
Glucagon like peptide 2 (GLP-2) is a naturally occurring hormone (or chemical messenger)
that is able to increase the surface area of the intestinal lining (or mucosal mass) and the
absorptive efficiency of the remaining intestine.
Intestinal failure patients in whom not only parts of the small bowel but also the large
bowel have had to be surgically removed have been shown to have a markedly impaired rise in
GLP-2 levels following meals, in contrast to patients with a preserved large bowel who have
increased levels of GLP-2 and are known to have much better functional adaptation.
From this we hypothesise that the GLP-2 level is directly related to, and could predict,
clinical recovery in intestinal failure as measured by Amount of parenteral nutrition
required Length of hospital stay Mortality
We also aim to compare GLP-2 levels of patients with acute intestinal failure with that of
patients with chronic intestinal failure as well as healthy controls
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Men and woman, aged 18 years of age or older at the time of signing the informed
consent form.
- Referral to or direct admission to St. Mark's Hospital.
- Acute intestinal failure resulting in TPN dependency as a result of major intestinal
resection performed during admission to St. Mark's or at the referring hospital.
Exclusion Criteria:
- Inability to give consent or comply with the study.
- Inability to take test meal (unable to be tested)
- Severe renal impairment (interference with GLP-2 excretion)
- Severe uncorrected anaemia (preventing additional blood-letting)
- Uncontrolled diabetes mellitus (risk of hyperglycaemia)
Locations and Contacts
Katharina Wallis, Email: katharina.wallis@ic.ac.uk
St Mark's Hospital, Harrow, Middlesex HA1 3UJ, United Kingdom; Recruiting Katharina Wallis, MD, Phone: 0044 797 101 4634, Email: katharina.wallis@ic.ac.uk Katharina Wallis, MD, Sub-Investigator
Additional Information
Web site devoted to the study of the glucagon-like peptides
Starting date: February 2005
Last updated: September 12, 2005
|